[go: up one dir, main page]

NO994903D0 - Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators - Google Patents

Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Info

Publication number
NO994903D0
NO994903D0 NO994903A NO994903A NO994903D0 NO 994903 D0 NO994903 D0 NO 994903D0 NO 994903 A NO994903 A NO 994903A NO 994903 A NO994903 A NO 994903A NO 994903 D0 NO994903 D0 NO 994903D0
Authority
NO
Norway
Prior art keywords
prophylaxis
treatment
prostate cancer
estrogen receptor
receptor modulators
Prior art date
Application number
NO994903A
Other languages
Norwegian (no)
Other versions
NO994903L (en
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994903D0 publication Critical patent/NO994903D0/en
Publication of NO994903L publication Critical patent/NO994903L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO994903A 1997-04-09 1999-10-08 Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators NO994903L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (2)

Publication Number Publication Date
NO994903D0 true NO994903D0 (en) 1999-10-08
NO994903L NO994903L (en) 1999-12-09

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994903A NO994903L (en) 1997-04-09 1999-10-08 Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators

Country Status (16)

Country Link
EP (1) EP0975629A4 (en)
JP (1) JP2001518900A (en)
KR (1) KR20010006218A (en)
CN (1) CN1259944A (en)
AU (1) AU6966198A (en)
BR (1) BR9808515A (en)
CA (1) CA2286204A1 (en)
EA (1) EA199900914A1 (en)
HU (1) HUP0003589A3 (en)
ID (1) ID24358A (en)
IL (1) IL132277A0 (en)
NO (1) NO994903L (en)
PL (1) PL336205A1 (en)
TR (1) TR199902701T2 (en)
WO (1) WO1998045288A1 (en)
ZA (1) ZA982819B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
RU2261716C1 (en) * 2004-02-24 2005-10-10 Долженков Сергей Дмитриевич Method for prophylaxis of suppurative-inflammatory complications in patients with benign prostate hyperplasia in post-operative period
JP5123935B2 (en) * 2006-05-22 2013-01-23 ホルモス メディカル リミテッド Method for treating chronic non-bacterial prostatitis using selective estrogen receptor modulators or aromatase inhibitors
JP5558358B2 (en) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド TRANS-clomiphene for metabolic syndrome
JP2015508825A (en) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド Combination therapy to treat androgen deficiency
CA2899030C (en) 2013-02-19 2021-03-09 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
SG64896A1 (en) * 1995-02-28 1999-05-25 Lilly Co Eli Benzothiophene compounds intermediates compositions and methods
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
EP0975629A4 (en) 2001-03-21
CN1259944A (en) 2000-07-12
WO1998045288A1 (en) 1998-10-15
ZA982819B (en) 1999-10-04
BR9808515A (en) 2001-06-19
HUP0003589A3 (en) 2002-02-28
JP2001518900A (en) 2001-10-16
EP0975629A1 (en) 2000-02-02
HUP0003589A2 (en) 2002-01-28
IL132277A0 (en) 2001-03-19
EA199900914A1 (en) 2000-04-24
PL336205A1 (en) 2000-06-05
AU6966198A (en) 1998-10-30
CA2286204A1 (en) 1998-10-15
ID24358A (en) 2000-07-13
TR199902701T2 (en) 2000-02-21
KR20010006218A (en) 2001-01-26
NO994903L (en) 1999-12-09

Similar Documents

Publication Publication Date Title
DK0925069T3 (en) Use of Cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer
NO993396L (en) Quinoline and quinoline compounds useful in therapy, especially in the treatment of benign prostatic hyperplasia
AU6393896A (en) Method for treating benign prostatic hyperplasia with thermal therapy
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
NO994903D0 (en) Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
IL120302A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
NO20002804D0 (en) Conjugates that can be used in the treatment of prostate cancer
HUT73678A (en) Compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
PT984777E (en) AILOSUBSTITUIDAL PILOTAZINES IN THE TREATMENT OF BENOSTINE PROSTATE HYPERPLASIA
NO20004141D0 (en) Newly substituted pyridinoarylpiperazines are useful in the treatment of benign prostate hyperplasia
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
KR950700746A (en) Compositions and Methods for Treating Benign Prostatic Hypertrophy
NO961113D0 (en) Treatment and prevention of prostate cancer
IL122316A0 (en) Melatonin agonists for treating benign prostatic hyperplasia
EP1435913A4 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AUPO410796A0 (en) Method of treating benign prostatic hyperplasia
AU1091200A (en) Method of treating prostate cancer with an adenovirus vector
IL122726A0 (en) Method and device for treating benign hyperplasia with thermal therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application